vs
Side-by-side financial comparison of BIOHARVEST SCIENCES INC. (BHST) and Prelude Therapeutics Inc (PRLD). Click either name above to swap in a different company.
BIOHARVEST SCIENCES INC. is the larger business by last-quarter revenue ($8.4M vs $6.5M, roughly 1.3× Prelude Therapeutics Inc).
BioHarvest Sciences Inc. is a biotechnology firm that develops and produces sustainable, high-purity plant-derived bioactive ingredients. It serves the nutraceutical, cosmetics, and pharmaceutical sectors, leveraging proprietary cell cultivation technology to create efficacious natural products without large-scale agricultural farming.
BHST vs PRLD — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.4M | $6.5M |
| Net Profit | — | $-19.7M |
| Gross Margin | 60.3% | — |
| Operating Margin | — | -314.1% |
| Net Margin | — | -303.5% |
| Revenue YoY | — | 116.7% |
| Net Profit YoY | — | 38.9% |
| EPS (diluted) | — | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $8.4M | $6.5M | ||
| Q2 25 | $8.1M | — | ||
| Q1 25 | $7.7M | — | ||
| Q3 24 | $6.5M | $3.0M | ||
| Q2 24 | $6.0M | — |
| Q3 25 | — | $-19.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $-32.3M | ||
| Q2 24 | — | — |
| Q3 25 | 60.3% | — | ||
| Q2 25 | 60.0% | — | ||
| Q1 25 | 58.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | — | -314.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | -1145.9% | ||
| Q2 24 | — | — |
| Q3 25 | — | -303.5% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | -1075.7% | ||
| Q2 24 | — | — |
| Q3 25 | — | $-0.26 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $-0.43 | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $55.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $58.5M |
| Total Assets | — | $94.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $55.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $153.6M | ||
| Q2 24 | — | — |
| Q3 25 | — | $58.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $156.4M | ||
| Q2 24 | — | — |
| Q3 25 | — | $94.8M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $197.2M | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-19.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-19.1M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $-27.3M | ||
| Q2 24 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $-27.4M | ||
| Q2 24 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | -912.0% | ||
| Q2 24 | — | — |
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
